Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 263Leukemia 190Leukemia, Lymphocytic, Chronic, B-Cell 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Myelodysplastic Syndromes 83Lymphoma 79Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Hematologic Neoplasms 62Lymphoma, Non-Hodgkin 61Lymphoma, Follicular 54Leukemia, Myeloid, Chronic-Phase 53Burkitt Lymphoma 51Lymphoma, Large B-Cell, Diffuse 47Lymphoma, B-Cell, Marginal Zone 45Lymphoma, Mantle-Cell 44Multiple Myeloma 42Leukemia, Myelomonocytic, Chronic 41Hodgkin Disease 41Myeloproliferative Disorders 38Neoplasms 37Lymphoma, Large-Cell, Immunoblastic 37Recurrence 31Leukemia, Myeloid, Accelerated Phase 28Congenital Abnormalities 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Biphenotypic, Acute 26Lymphoma, T-Cell, Cutaneous 25Blast Crisis 24Waldenstrom Macroglobulinemia 23Leukemia, Myelomonocytic, Acute 23

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pathologic Processes × Other hematologic neoplasm × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡